ATE496917T1 - Haptene, immunogene, antikörper und konjugate für 2-oxo-3-hydroxy lsd - Google Patents
Haptene, immunogene, antikörper und konjugate für 2-oxo-3-hydroxy lsdInfo
- Publication number
- ATE496917T1 ATE496917T1 AT02080687T AT02080687T ATE496917T1 AT E496917 T1 ATE496917 T1 AT E496917T1 AT 02080687 T AT02080687 T AT 02080687T AT 02080687 T AT02080687 T AT 02080687T AT E496917 T1 ATE496917 T1 AT E496917T1
- Authority
- AT
- Austria
- Prior art keywords
- lsd
- oxo
- present
- hydroxy
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/814—Pregnancy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01205057 | 2001-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496917T1 true ATE496917T1 (de) | 2011-02-15 |
Family
ID=27589058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02080687T ATE496917T1 (de) | 2001-12-20 | 2002-12-17 | Haptene, immunogene, antikörper und konjugate für 2-oxo-3-hydroxy lsd |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7115718B2 (de) |
| EP (1) | EP1321466B1 (de) |
| CN (1) | CN1300139C (de) |
| AT (1) | ATE496917T1 (de) |
| DE (1) | DE60239042D1 (de) |
| ES (1) | ES2361907T3 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794496B2 (en) * | 2000-04-07 | 2004-09-21 | Roche Diagnostics Corporation | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD |
| EP2336147B1 (de) | 2003-12-17 | 2014-04-30 | Janssen Alzheimer Immunotherapy | Beta-Immunogen-Peptidträgerkonjugate und Herstellungsverfahren dafür |
| US20060223998A1 (en) * | 2005-03-30 | 2006-10-05 | Fang-Jie Zhang | Synthetic LSD metabolite for preparing haptens used in an LSD metabolite immunoassay |
| EP1988094B1 (de) * | 2006-02-23 | 2014-06-11 | Japan Science and Technology Agency | Hapten-verbindung und antikörper |
| CN102707047A (zh) * | 2012-06-05 | 2012-10-03 | 南通市产品质量监督检验所 | 快速检测麦角生物碱的胶体金检测卡及其制备方法 |
| CN102707046A (zh) * | 2012-07-13 | 2012-10-03 | 江苏省苏微微生物研究有限公司 | 一种麦角生物碱多残留分析的酶联免疫分析测试盒及其检测方法 |
| GB201217938D0 (en) * | 2012-10-08 | 2012-11-21 | Randox Lab Ltd | Immunoassays for meperidine and metabolites |
| BR112019026434A2 (pt) | 2017-06-14 | 2020-07-14 | Virometix Ag | peptídeos cíclicos para proteção contra vírus sincicial respiratório |
| EP3897708A1 (de) | 2018-12-20 | 2021-10-27 | Virometix AG | Lipopeptidbausteine und synthetische virusähnliche partikel |
| CN110187094A (zh) * | 2019-06-27 | 2019-08-30 | 贵州盛世康生物科技有限公司 | 一种5-羟基吲哚乙酸测定试剂 |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| WO2022063990A1 (en) | 2020-09-28 | 2022-03-31 | Dbv Technologies | Particle comprising an rsv-f protein for use in rsv vaccination |
| CN112924665B (zh) * | 2021-02-19 | 2023-10-03 | 山东莱博生物科技有限公司 | 一种抗体辣根过氧化物酶标记物及其制备与应用 |
| CN117355302A (zh) | 2021-04-30 | 2024-01-05 | 思维医学股份有限公司 | Lsd盐晶体形式 |
| JP2024529727A (ja) | 2021-08-19 | 2024-08-08 | マインド メディシン, インコーポレイテッド | 治療適用のためのd-リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤 |
| EP4719390A2 (de) * | 2023-05-31 | 2026-04-08 | Cacti, Inc. | Neuroplastigenmodulatoren zur behandlung von schmerzen, juckreiz und nervenläsionen |
| KR20260040241A (ko) | 2023-07-12 | 2026-03-24 | 비로메틱스 아게 | 폐렴구균 항원의 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207396B1 (en) * | 1995-11-20 | 2001-03-27 | Microgenics Corporation | Immunoassay reagents and methods for determination of LSD and LSD metabolites |
| US6063908A (en) * | 1996-07-02 | 2000-05-16 | Roche Diagnostics Corporation | Reagents for lysergic acid diethylamide immunoassay |
| US6306616B1 (en) * | 1998-03-27 | 2001-10-23 | Microgenics Corporation | Adsorption type confirmatory assays |
| US6794496B2 (en) * | 2000-04-07 | 2004-09-21 | Roche Diagnostics Corporation | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD |
-
2002
- 2002-12-17 EP EP02080687A patent/EP1321466B1/de not_active Expired - Lifetime
- 2002-12-17 AT AT02080687T patent/ATE496917T1/de not_active IP Right Cessation
- 2002-12-17 ES ES02080687T patent/ES2361907T3/es not_active Expired - Lifetime
- 2002-12-17 DE DE60239042T patent/DE60239042D1/de not_active Expired - Lifetime
- 2002-12-20 US US10/326,771 patent/US7115718B2/en not_active Expired - Lifetime
- 2002-12-20 CN CNB021400350A patent/CN1300139C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60239042D1 (de) | 2011-03-10 |
| US7115718B2 (en) | 2006-10-03 |
| ES2361907T3 (es) | 2011-06-24 |
| EP1321466B1 (de) | 2011-01-26 |
| CN1300139C (zh) | 2007-02-14 |
| CN1450065A (zh) | 2003-10-22 |
| EP1321466A1 (de) | 2003-06-25 |
| US20030143655A1 (en) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60239042D1 (de) | Haptene, Immunogene, Antikörper und Konjugate für 2-oxo-3-hydroxy LSD | |
| ATE492565T1 (de) | Immunogene, antikörper und konjugate für ketamin und dessen metaboliten | |
| ATE205602T1 (de) | Verfahren und gerät zum nachweis und zur quantifizierung von glukose in körperflüssigkeiten | |
| ATE400813T1 (de) | Tumormarker für frühes krebsstadium | |
| BRPI9910394B8 (pt) | molÉculas de ligaÇço especÍfica para cintigrafia e conjugados contendo as mesmas | |
| ATE256658T1 (de) | Funktionelle vitamin-d-derivate und verfahren zur bestimmung von 25-hydroxy- und 1alpha,25- dihydroxy-vitamin-d | |
| DE69121844D1 (de) | Immunotest für Cyclosporin | |
| DE69828432D1 (de) | Verfahren, kits und zusammenfassungen mit beziehung zu linearen baken | |
| EE200300128A (et) | Meetod allergeeniga seostuva immunoglobuliini detekteerimiseks proovis, patsiendi allergiate in vitro diagnoosimeetod, mikromaatrikskiip ja komplekt | |
| GR910100453A (el) | Ανάλυση και διάταξη συγκολλήσεως στήλης. | |
| DE60042066D1 (de) | Chimärische dr4 antikörper und ihre verwendung | |
| DE59406903D1 (de) | Homobidentale, trifunktionelle Maleinimid-Linker, und ihre Verwendung in immunologisch aktiven Konjugaten | |
| ATE408843T1 (de) | Verfahren und kit zum nachweis oder zur bestimmung von 3,4-methylendioxymethamphetamin | |
| DE69604920D1 (de) | Verwendung einer phycobiliprotein-peptidkomplexverbindung als fluoreszenzlabel | |
| DE60207016D1 (de) | Verfahren und Kit zur Quantifizierung von Beta-Laktam Penizillinen | |
| WO2003106649A3 (en) | CONJUGATE TEST AND USES THEREOF | |
| AU2002311679A1 (en) | A differential labelling method | |
| DK1173766T3 (da) | Isoform af tenascin-C som markör for neoplasier | |
| DE69928888D1 (de) | Reduziertes Cortisolkonjugat | |
| ATE52251T1 (de) | Histamin-derivate, immunogen-konjugate und dadurch induzierte antikoerper. | |
| DE59911588D1 (de) | Brunnenrohr | |
| ATE466884T1 (de) | Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest | |
| DE69922680D1 (de) | Detektion und quantifikation von vancomycin in den biologischen flüssigkeiten | |
| EP1312923A3 (de) | Verfahren und Kit zum Nachweis, oder zum Quantifizieren von, Metaboliten von Fentanyl und Metaboliten von Fentanyl Analogen | |
| DE602005023784D1 (de) | Blockierter enzymsondenkomplex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |